HOME >> MEDICINE >> NEWS
Government spin on success of NHS cataract privatisation criticised

Patricia Hewitt, the UK's Secretary of State for Health, is wrong to announce that independent sector-treatment centers (IS-TCs) reduced waiting times for cataract operations, states the author of a correspondence letter in this week's issue of The Lancet.

Patricia Hewitt recently announced to the Fabian Society that "the first wave of IS-TCs has already brought down the waiting times for cataract operations to three months, a target achieved four years earlier than promised". However, ophthalmic surgeon Simon Kelly states that it is the National Health Service (NHS) ophthalmic staff and not the IS-TCs that have delivered improved services to English cataract patients. The letter follows the recent Lancet editorial, (Lancet 2005; 366:1293), which called for the UK government's programme of wide-ranging privatisation of the NHS to be stopped until there is independent evidence on the effect of the policy.

Kelly states that targeted capital to construct new NHS ophthalmic facilities and improved practice arising from Action on Cataracts (an NHS scheme run along with the Royal College of Ophthalmologists) not IS-TCs increased the rate of cataract surgery from 170,000 operations in 1998/99 to over 300,000 operations per year by 2003/04. He also notes that the South African corporation Netcare, which won the bid for the Government's mobile cataract IS-TC scheme, will have to be paid for over 44 000 cataract operations in contracts arranged over 5 years, irrespective of whether they are needed or even carried out.


'"/>

Contact: Joe Santangelo
j.santangelo@elsevier.com
1-212-633-3810
Lancet
10-Nov-2005


Page: 1

Related medicine news :

1. Government fails sleepy Judge Dodd
2. Governments reliance on free market economics makes essential drug prices too high for the poor
3. Frazer welcomes Federal Government decision on Gardasil
4. Government scheme to improve health and well-being of deprived families called into question
5. Governments preparation for bird flu outbreak welcome
6. Government pledge on access to medicines welcomed
7. Government reforms may bring an end to free healthcare
8. Governments need to act transparently to stem public anxiety about a human influenza pandemic
9. Government plans for NHS more aggressive than Tories ever were
10. Government policy changes lead to dramatic drop in heart disease deaths in Poland
11. Controlling prescription drug expenditures: a case report of success

Post Your Comments:
(Date:3/2/2015)... March 02, 2015 Over the last ... among leading vendors seeking to expand their geographic presence ... is expected to reach $6.2 billion by 2019 at ... America including the U.S. and Canada and a major ... However developing regions such as Asia-Pacific including China and ...
(Date:3/2/2015)... The minimally invasive surgical instruments ... of 6.1% to reach $14,133.0 million by 2019 ... such as advantages of minimally invasive surgeries over ... minimally invasive surgeries and increasing number of surgical ... global minimally invasive surgical instruments market. , For ...
(Date:3/2/2015)... 02, 2015 LegitScript, LLC, ... certification programs, including those for Internet pharmacy ... safety and classification, has launched a certification ... The new program, called iCareRx , ... regarding the identity of the owner/operator of ...
(Date:3/2/2015)... Atlantic Information Services, Inc. (AIS) is pleased to ... Plans: 2015 , the all-new 12th edition of the ... market, with enrollment data and contact information for health ... as a printed book containing the full directory and ... and charts, as well as an electronic version, AIS’s ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 Regulatory ... focused on quality, regulatory and technical consulting, announces ... Chief Operating Officer. , Before joining RCA, ... leading R&D teams in all aspects of developing ... positions at Covidien (Medtronic), Regulatory Compliance Associates Inc., ...
Breaking Medicine News(10 mins):Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 2Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 3Health News:Minimally Invasive Surgical Instrument Market - Global Forecast to 2019 - New Report by MarketsandMarkets 2Health News:LegitScript Launches Certification Program for Internet Eyeglass Sellers 2Health News:Now Available from AIS: 12th Edition of Annual Book Containing Health Plan Enrollment Data, Contact Information 2Health News:Regulatory Compliance Associates® Inc. Welcomes Seyed Khorashahi as Chief Operating Officer 2
(Date:3/2/2015)... 2015  DURECT Corporation (Nasdaq: DRRX ... the successful completion of a Phase 1 clinical ... DUR-928 is an endogenous, small-molecule, new chemical entity ... diseases such as nonalcoholic fatty liver disease (NAFLD) ... injuries such as acute kidney injury (AKI).        ...
(Date:3/2/2015)... 2, 2015  Intrexon Corporation (NYSE: ... announced its fourth quarter and full year results ... Recent Developments: , Acquired ActoGeniX, a European ... in cellular therapeutics and other innovative products.  Its ... food-grade microbes ( Lactococcus lactis ) to generate ...
(Date:3/2/2015)... Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today reported financial ... 31, 2014. Financial highlights for the fourth quarter include revenues ... or $0.04 per share. This compares to revenues of $12.5 ... per share, for the fourth quarter of 2013. Financial highlights ... and a net loss of $68.4 million, or $0.56 per ...
Breaking Medicine Technology:DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 2DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 3DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 4DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 5Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 2Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 3Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 4Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 5Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 6Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 7Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 8Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 9Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 10Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 11Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 12Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 13Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 14Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 15Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 16Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 17Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 18Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 19Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 20Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 21Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 22Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 23Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 24Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 2Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 3Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 4Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 5Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 6Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 7Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 8Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 9
Cached News: